Farah Yasmin, H. Najeeb, Unaiza Naeem, Abdul Moeed, Abdul Raafe Atif, M. Asghar, Nayef Nimri, M. Saleem, D. Bandyopadhyay, C. Krittanawong, Mohammed Mahmmoud Fadelallah Eljack, M. J. Tahir, F. Waqar
tlooto Summary
This study provides an in‐depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, and pulmonary embolism.
Abstract
Since publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID‐19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study provides an in‐depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic events, portal vein thrombosis, coronary thrombosis, microvascular small bowel thrombosis), and pulmonary embolism.
Citation format
YASMIN, Farah, et al. Adverse events following COVID‐19 mrna vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immunity Inflammation and Disease, 2023, 11.